

Kun-Huei Yeh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5892050/publications.pdf>

Version: 2024-02-01

162
papers

9,329
citations

109321

35
h-index

42399

92
g-index

166
all docs

166
docs citations

166
times ranked

11528
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	5.3	9
2	A randomized, double-blind, phase III study comparing trifluridine/tipiracil hydrochloride therapy versus placebo in resected colorectal cancer patients who are positive for blood circulating tumor DNA after standard adjuvant therapy (EPOC 1905): ALTAIR trial in CIRCULATE-Japan (trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS215-TPS215.	1.6	3
3	A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS364-TPS364.	1.6	0
4	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS224-TPS224.	1.6	3
5	A pilot study of metabolomic pathways associated with fatigue in patients with colorectal cancer receiving chemotherapy. <i>European Journal of Oncology Nursing</i> , 2022, 56, 102096.	2.1	2
6	Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , 2022, 14, 1005.	3.7	11
7	Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer. <i>Journal of the Formosan Medical Association</i> , 2022, , .	1.7	3
8	A Pilot Study of Metabolomic Pathways Associated With Fatigue in Survivors of Colorectal Cancer. <i>Biological Research for Nursing</i> , 2021, 23, 42-49.	1.9	8
9	Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 293-302.	1.7	4
10	Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. <i>Oncolmmunology</i> , 2021, 10, 1973710.	4.6	4
11	Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 2023-2031.	1.7	4
12	Spectrum of cancer patients receiving renal biopsy. <i>Journal of the Formosan Medical Association</i> , 2021, 121, 152-152.	1.7	0
13	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	5.3	61
14	Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing. <i>Scientific Reports</i> , 2021, 11, 9080.	3.3	6
15	Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort. <i>British Journal of Cancer</i> , 2021, 125, 48-54.	6.4	1
16	Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF- κ B-related signaling. <i>Cancer Cell International</i> , 2021, 21, 436.	4.1	4
17	Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. <i>Journal of Biomedical Science</i> , 2021, 28, 75.	7.0	7
18	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	5.3	45

#	ARTICLE	IF	CITATIONS
19	Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 97-105.	1.7	3
20	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	5.3	155
21	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 <scp>CONCUR</scp> trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1307-1316.	2.8	8
22	A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. <i>Haematologica</i> , 2020, 105, e349-e354.	3.5	5
23	Complement C1q mediates the expansion of periportal hepatic progenitor cells in senescence-associated inflammatory liver. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6717-6725.	7.1	9
24	A nationwide survey of fatigue in cancer patients in Taiwan: an unmet need. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 693-700.	1.3	10
25	Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4523-4523.	1.6	9
26	Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , 2019, 11, 547.	3.7	30
27	CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer. <i>Oncology</i> , 2019, 96, 156-163.	1.9	6
28	Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1024-1030.	1.7	5
29	MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)â€“based combinations in gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS467-TPS467.	1.6	12
30	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	1.6	524
31	A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. <i>Anticancer Research</i> , 2018, 38, 4805-4812.	1.1	3
32	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. <i>Future Oncology</i> , 2018, 14, 2031-2044.	2.4	20
33	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2018, 392, 123-133.	13.7	984
34	The prognostic role of CpG island methylator phenotype in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-667.	1.6	9
35	Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. <i>Anticancer Research</i> , 2018, 38, 1569-1577.	1.1	9
36	Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability. <i>Journal of Cancer Research and Practice</i> , 2017, 4, 72-75.	0.2	1

#	ARTICLE	IF	CITATIONS
37	Expressions of the CagA protein and CagA-signaling molecules predict <i>Helicobacter pylori</i> dependence of early-stage gastric DLBCL. <i>Blood</i> , 2017, 129, 188-198.	1.4	20
38	First-line antibiotic therapy in <i>Helicobacter pylori</i> -negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. <i>Scientific Reports</i> , 2017, 7, 14333.	3.3	21
39	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471.	13.7	1,749
40	The B-cell-activating factor signalling pathway is associated with <i>Helicobacter pylori</i> independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21). <i>Journal of Pathology</i> , 2017, 241, 420-433.	4.5	13
41	Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer. <i>Supportive Care in Cancer</i> , 2017, 25, 533-539.	2.2	12
42	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. <i>Clinical Colorectal Cancer</i> , 2017, 16, e73-e88.	2.3	19
43	Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study. <i>Annals of Oncology</i> , 2017, 28, iii10.	1.2	6
44	Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. <i>Cancer Research and Treatment</i> , 2017, 49, 851-868.	3.0	50
45	Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis. <i>Medical Oncology</i> , 2017, 34, 143.	2.5	6
46	Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3567-3567.	1.6	3
47	Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: An interim analysis (IA) from the prospective, observational CORRELATE study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 700-700.	1.6	6
48	Distinct Clinicopathological Features and Prognosis of <i>Helicobacter pylori</i> Negative Gastric Cancer. <i>PLoS ONE</i> , 2017, 12, e0170942.	2.5	33
49	Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. <i>PLoS ONE</i> , 2017, 12, e0180628.	2.5	4
50	Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study. <i>Anticancer Research</i> , 2017, 37, 7095-7104.	1.1	6
51	Comparison of irinotecan and oxaliplatin as adjuvant chemotherapy for patients with resectable synchronous colon cancer plus liver-confined metastases: A retrospective nationwide database study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 624-624.	1.6	0
52	A phase II study of early FDG-PET evaluation after one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy: Final report.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4042-4042.	1.6	14
53	Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 2004-2012.	2.8	5
54	BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer. <i>Medical Oncology</i> , 2016, 33, 39.	2.5	22

#	ARTICLE	IF	CITATIONS
55	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. <i>BMC Cancer</i> , 2016, 16, 327.	2.6	42
56	Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11937-11942.	7.1	37
57	Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. <i>Journal of Hematology and Oncology</i> , 2016, 9, 29.	17.0	21
58	Frequent <i>BRAF</i> mutation in early-onset colorectal cancer in Taiwan: association with distinct clinicopathological and molecular features and poor clinical outcome. <i>Journal of Clinical Pathology</i> , 2016, 69, 319-325.	2.0	8
59	Results of Phase II trial of ALIY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 134-134.	1.6	9
60	A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 335-335.	1.6	42
61	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 7275.	3.3	26
62	The recurrence patterns and post-recurrence survivals in patients with locally advanced esophageal squamous cell carcinoma (ESCC) treated with preoperative paclitaxel/cisplatin-based chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 80-80.	1.6	0
63	Low-dose nab-paclitaxel-based combination chemotherapy in heavily-pretreated pancreatic or ampullary cancer patients: Taiwanese single-center case series.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15695-e15695.	1.6	0
64	Association of the number of dissected lymph node (LN) with the survivals of locally advanced esophageal squamous cell carcinoma (ESCC) patients received preoperative chemoradiotherapy (CRT) followed by surgery.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15543-e15543.	1.6	0
65	Efficacy of frontline antibiotics therapy in the treatment of <i>Helicobacter pylori</i> -negative gastric low-grade mucosa-associated lymphoid tissue lymphoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19024-e19024.	1.6	0
66	<i>Helicobacter pylori</i> CagA Translocation Is Closely Associated With the Expression of CagA-signaling Molecules in Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 761-766.	3.7	19
67	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 619-629.	10.7	574
68	Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 819-827.	1.3	19
69	Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1481-1489.	1.1	15
70	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan. <i>Clinical Colorectal Cancer</i> , 2015, 14, 177-184.e4.	2.3	36
71	Young patients with colorectal cancer have increased risk of second primary cancers. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 1029-1035.	1.3	11
72	Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor α in female hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2015, 136, 761-770.	5.1	37

#	ARTICLE	IF	CITATIONS
73	Heterogeneous cell origin of <i>Helicobacter pylori</i> -dependent high-grade gastric lymphomas.. Journal of Clinical Oncology, 2015, 33, e19520-e19520.	1.6	1
74	Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. Journal of Clinical Oncology, 2015, 33, 697-697.	1.6	1
75	Postchemoradiotherapy (CRT) pathologic stage classified by American Joint Committee on Cancer (AJCC) staging system to predict prognosis of patients with locally advanced esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology, 2015, 33, 158-158.	1.6	0
76	Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 566-566.	1.6	0
77	Primary tumor site as a useful predictor for cetuximab efficacy in KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, e14592-e14592.	1.6	0
78	Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations. Anticancer Research, 2015, 35, 4207-14.	1.1	4
79	Type 2 Diabetes Mellitus Is Associated With Increased Mortality in Chinese Patients Receiving Curative Surgery for Colon Cancer. Oncologist, 2014, 19, 951-958.	3.7	24
80	Beware imposters: MA1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line. A reply: Despite the same STR, MA1 and Pfeiffer are cytogenetically diverse. Genes Chromosomes and Cancer, 2014, 53, 211-213.	2.8	3
81	Unmet Supportive Care Needs of Patients With Colorectal Cancer: Significant Differences by Type D Personality. Oncology Nursing Forum, 2014, 41, E3-E11.	1.2	23
82	Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers. Supportive Care in Cancer, 2014, 22, 1189-1197.	2.2	13
83	A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 799-806.	2.3	14
84	Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i> -Amplified Advanced Gastric Cancer in Asian Populations: TyTAN A Randomized, Phase III Study. Journal of Clinical Oncology, 2014, 32, 2039-2049.	1.6	524
85	Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. Oncology, 2014, 87, 104-113.	1.9	28
86	Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients. PLoS ONE, 2014, 9, e86789.	2.5	18
87	Risk of second primary malignancies in young patients with colorectal cancer.. Journal of Clinical Oncology, 2014, 32, e14533-e14533.	1.6	0
88	Association of <i>Helicobacter pylori</i> CagA translocation with the expression of CagA-signaling transduction molecules in gastric mucosa-associated lymphoid tissue lymphoma.. Journal of Clinical Oncology, 2014, 32, 8571-8571.	1.6	0
89	Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review. Anticancer Research, 2014, 34, 3695-9.	1.1	6
90	Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. Journal of Clinical Oncology, 2013, 31, 3935-3943.	1.6	411

#	ARTICLE	IF	CITATIONS
91	Management of gastric cancer in Asia: resource-stratified guidelines. <i>Lancet Oncology</i> , The, 2013, 14, e535-e547.	10.7	418
92	Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. <i>International Journal of Cancer</i> , 2013, 132, 1451-1462.	5.1	21
93	Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer. <i>Translational Oncology</i> , 2013, 6, 363-369.	3.7	9
94	Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients. <i>Annals of Oncology</i> , 2013, 24, 463-468.	1.2	32
95	No evidence of t(11;22)(q23;q11) in the Ma-1 cell line-A reply. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 593-594.	2.8	1
96	Regular statin users and colorectal cancer (CRC) prognosis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3554-3554.	1.6	1
97	Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4099-4099.	1.6	1
98	ADAR2-Mediated Editing of miR-214 and miR-122 Precursor and Antisense RNA Transcripts in Liver Cancers. <i>PLoS ONE</i> , 2013, 8, e81922.	2.5	30
99	Association of diabetes mellitus with increased mortality in patients receiving curative surgery for colon cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 399-399.	1.6	0
100	Prevalence of gene amplifications of SOX-2, c-MET, and FGFR1 in Asian patients with esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15127-e15127.	1.6	0
101	Clinicopathologic features and treatment outcome of primary intestinal non-Hodgkin lymphoma: A single center experience.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19523-e19523.	1.6	0
102	Effective treatment of aggressive B-cell lymphomas by downregulated NIK-induced noncanonical NF- κ B pathway activation through inhibition of BAFF.. <i>Journal of Clinical Oncology</i> , 2013, 31, e13554-e13554.	1.6	0
103	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. <i>Journal of Clinical Oncology</i> , 2013, 31, e14501-e14501.	1.6	0
104	Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. <i>Blood</i> , 2012, 119, 4838-4844.	1.4	123
105	Estrogen Receptor α Represses Transcription of HBV Genes via Interaction With Hepatocyte Nuclear Factor 4 α . <i>Gastroenterology</i> , 2012, 142, 989-998.e4.	1.3	105
106	KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e50701.	2.5	44
107	Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression. <i>Gastric Cancer</i> , 2012, 15, 265-280.	5.3	17
108	Author's reply: Vitamin A and gastric cancer risk. <i>Gastric Cancer</i> , 2012, 15, 344-344.	5.3	16

#	ARTICLE	IF	CITATIONS
109	Safety of everolimus (EVE) in Asian patients (pts) with advanced gastric cancer (AGC) enrolled in the phase III GRANITE-1 study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4081-4081.	1.6	0
110	Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. <i>European Journal of Cancer</i> , 2011, 47, 1244-1257.	2.8	17
111	Recent Advances in the Treatment of Metastatic Colorectal Cancer in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2011, 110, 1-3.	1.7	1
112	Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. <i>Anti-Cancer Drugs</i> , 2011, 22, 290-298.	1.4	4
113	A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1281-1289.	2.3	5
114	t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1387-1395.	2.3	14
115	Establishment of a novel MALT lymphoma cell line, ma1, from a patient with t(14;18)(q32;q21)-positive <i>Helicobacter Pylori</i> -independent Gastric MALT Lymphoma. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 908-921.	2.8	9
116	Depletion of β -catenin from mature hepatocytes of mice promotes expansion of hepatic progenitor cells and tumor development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18384-18389.	7.1	33
117	Personality Trait and Quality of Life in Colorectal Cancer Survivors. <i>Oncology Nursing Forum</i> , 2011, 38, E221-E228.	1.2	15
118	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. <i>Lung Cancer</i> , 2009, 64, 346-351.	2.0	43
119	Down-regulation of Phospho-Akt Is a Major Molecular Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells. <i>Cancer Research</i> , 2008, 68, 6698-6707.	0.9	109
120	Overexpression of B cell-activating factor of TNF family (BAFF) is associated with <i>Helicobacter pylori</i> -independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. <i>Blood</i> , 2008, 112, 2927-2934.	1.4	52
121	Long-term Follow-up of Gastrectomized Patients With Mucosa-associated Lymphoid Tissue Lymphoma. <i>Annals of Surgery</i> , 2008, 247, 265-269.	4.2	17
122	Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. <i>Anti-Cancer Drugs</i> , 2007, 18, 703-708.	1.4	8
123	Disseminated <i>Mycobacterium kansasii</i> infection in an HIV-negative patient presenting with mimicking multiple bone metastases. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 54, 211-216.	1.8	9
124	A Pathway for Tumor Necrosis Factor- α -induced Bcl10 Nuclear Translocation. <i>Journal of Biological Chemistry</i> , 2006, 281, 167-175.	3.4	39
125	Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. <i>Anti-Cancer Drugs</i> , 2005, 16, 739-742.	1.4	2
126	Nuclear expression of BCL10 or nuclear factor kappa B helps predict <i>Helicobacter pylori</i> -independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). <i>Blood</i> , 2005, 106, 1037-1041.	1.4	74

#	ARTICLE	IF	CITATIONS
127	Survival Outcome of Inoperable Non-Small Cell Lung Cancer Patients Receiving Conventional Dose Epirubicin and Paclitaxel as First-Line Treatment. <i>Oncology</i> , 2005, 68, 350-355.	1.9	5
128	Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic Gastric Cancer. <i>Oncology</i> , 2005, 69, 88-95.	1.9	19
129	Expression of CD86 and increased infiltration of NK cells are associated with <i>Helicobacter pylori</i> -dependent state of early stage high-grade gastric MALT lymphoma. <i>World Journal of Gastroenterology</i> , 2005, 11, 4357.	3.3	17
130	Nuclear Expression of BCL10 or Nuclear Factor Kappa B Predicts <i>Helicobacter pylori</i> -Independent Status of Early-Stage, High-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphomas. <i>Journal of Clinical Oncology</i> , 2004, 22, 3491-3497.	1.6	59
131	Suppression of MEK/ERK Signaling Pathway Enhances Cisplatin-induced NF- κ B Activation by Protein Phosphatase 4-mediated NF- κ B p65 Thr Dephosphorylation. <i>Journal of Biological Chemistry</i> , 2004, 279, 26143-26148.	3.4	97
132	Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. <i>Oncogene</i> , 2004, 23, 3580-3588.	5.9	83
133	Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. <i>Anti-Cancer Drugs</i> , 2004, 15, 371-376.	1.4	31
134	Recent advances in therapy for gastric cancer. <i>Journal of the Formosan Medical Association</i> , 2004, 103, 171-85.	1.7	5
135	Involvement of nuclear transcription factor- κ B in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells. <i>Biochemical Pharmacology</i> , 2003, 66, 25-33.	4.4	38
136	High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma. <i>Anticancer Research</i> , 2003, 23, 5133-7.	1.1	2
137	Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF- κ B activation. <i>Biochemical Pharmacology</i> , 2002, 63, 1423-1430.	4.4	126
138	High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. <i>International Journal of Cancer</i> , 2002, 101, 519-525.	5.1	109
139	P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. <i>International Journal of Cancer</i> , 2002, 97, 451-457.	5.1	65
140	A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. <i>Anticancer Research</i> , 2002, 22, 3621-7.	1.1	7
141	The F-Box Protein SKP2 Binds to the Phosphorylated Threonine 380 in Cyclin E and Regulates Ubiquitin-Dependent Degradation of Cyclin E. <i>Biochemical and Biophysical Research Communications</i> , 2001, 281, 884-890.	2.1	53
142	Nuclear Extracellular Signal-Regulated Kinase 2 Phosphorylates p53 at Thr55 in Response to Doxorubicin. <i>Biochemical and Biophysical Research Communications</i> , 2001, 284, 880-886.	2.1	34
143	Minimal Toxicity to Myeloid Progenitor Cells of Weekly 24-Hr Infusion of High-Dose 5-Fluorouracil: Direct Evidence from Colony Forming Unit-Granulocyte and Monocyte (CFU-GM) Clonogenic Assay. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2000, 86, 122-124.	0.0	1
144	Minimal Toxicity to Myeloid Progenitor Cells of Weekly 24-Hr Infusion of High-Dose 5-Fluorouracil: Direct Evidence from Colony Forming Unit-Granulocyte and Monocyte (CFU-GM) Clonogenic Assay. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2000, 86, 122-124.	0.0	9

#	ARTICLE	IF	CITATIONS
145	p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27. <i>Current Biology</i> , 1999, 9, 661-S2.	3.9	850
146	High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma. , 1999, 86, 415-420.		14
147	Quiescent nasal T/NK cell lymphoma manifested as primary central nervous system lymphoma. <i>American Journal of Hematology</i> , 1999, 60, 161-163.	4.1	32
148	High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancers. <i>Breast Cancer Research and Treatment</i> , 1998, 49, 237-244.	2.5	2
149	5-Fluorouracil-related encephalopathy: at least two distinct pathogenetic mechanisms exist - reply. <i>British Journal of Cancer</i> , 1998, 77, 1711-1712.	6.4	3
150	High expression of thymidylate synthase is Associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. <i>Cancer</i> , 1998, 82, 1626-1631.	4.1	93
151	Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma. , 1998, 82, 1946-1951.		53
152	Gastric cancer associated with acute disseminated intravascular coagulation: successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin. <i>British Journal of Haematology</i> , 1998, 100, 769-772.	2.5	29
153	T-cell Malignant Lymphoma With Conjunctival Involvement. <i>American Journal of Ophthalmology</i> , 1998, 125, 717-719.	3.3	13
154	Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. <i>Biochemical Pharmacology</i> , 1998, 55, 523-531.	4.4	54
155	Relatively Low Expression of Multidrug Resistance-1 (MDR-1) and Its Possible Clinical Implication in Gastric Cancers. <i>Journal of Clinical Gastroenterology</i> , 1998, 26, 274-278.	2.2	10
156	Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Advanced Gastric Cancers. <i>Oncology</i> , 1997, 54, 275-280.	1.9	56
157	Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. , 1996, 77, 872-877.		30
158	Primary T Cell Leptomeningeal Lymphoma – Successful Treatment with Systemic Chemotherapy. <i>Oncology</i> , 1995, 52, 501-504.	1.9	11
159	Long-term disease-free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes. <i>British Journal of Haematology</i> , 1995, 89, 914-916.	2.5	10
160	Panhypopituitarism Caused by Solitary Parasellar Metastasis From Lung Cancer. <i>Chest</i> , 1994, 105, 951-953.	0.8	22
161	Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. <i>Gastroenterology</i> , 1994, 107, 1514-1518.	1.3	86
162	Revisiting the Full Spectrum of Helicobacter pylori-Related Gastric Lymphoma. , 0, , .		0